Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dextromethorphan Hydrobromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mucinex Children's Launches Mighty Chews
Details : Mighty Chews consisting, Dextromethorphan HBr, is the first and only over-the-counter medicated children's soft chew for cough relief.
Product Name : Mighty Chews
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 30, 2024
Lead Product(s) : Dextromethorphan Hydrobromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Flurbiprofen
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Recipient : University of Melbourne
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 21, 2023
Lead Product(s) : Flurbiprofen
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Recipient : University of Melbourne
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibuprofen
Therapeutic Area : Dental and Oral Health
Study Phase : Phase III
Sponsor : Premier Research Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 02, 2022
Lead Product(s) : Ibuprofen
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase III
Sponsor : Premier Research Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prebiotic
Therapeutic Area : Sleep
Study Phase : Undisclosed
Recipient : Northumbria University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
February 15, 2022
Lead Product(s) : Prebiotic
Therapeutic Area : Sleep
Highest Development Status : Undisclosed
Recipient : Northumbria University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Combined Paracetamol and Ibuprofen Medicine Approved for General Sale
Details : Nuromol is used for mild to moderate pain associated with migraine, headache, backache, period pain, dental pain, rheumatic, muscular pain, pain of non-serious arthritis, cold-flu symptoms, sore throat & fever when paracetamol or ibuprofen alone have not...
Product Name : Nuromol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 16, 2021
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 24, 2018
Lead Product(s) : Guaifenesin
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 30, 2018
Lead Product(s) : Guaifenesin
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibuprofen
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Simbec Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Nurofen Ibuprofen Orodispersible Tablet Disintegration Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 05, 2018
Lead Product(s) : Ibuprofen
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Simbec Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Guaifenesin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mucinex® ER 600 mg Bi-Layer Tablet Fed and Fasted
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2018
Lead Product(s) : Guaifenesin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Guaifenesin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 23, 2018
Lead Product(s) : Guaifenesin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable